Biomedicines (Jan 2023)

Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience

  • Irene Persano,
  • Massimiliano Cani,
  • Benedetta Del Rio,
  • Giorgia Ferrari,
  • Edoardo Garbo,
  • Elena Parlagreco,
  • Chiara Pisano,
  • Valeria Cetoretta,
  • Marco Donatello Delcuratolo,
  • Fabio Turco,
  • Alessandro Audisio,
  • Cristina Cecchi,
  • Gianmarco Leone,
  • Valerio Maria Napoli,
  • Valentina Bertaglia,
  • Valentina Bianco,
  • Enrica Capelletto,
  • Carmen D’Amiano,
  • Massimo Di Maio,
  • Martina Gianetta,
  • Silvia Novello,
  • Francesco Passiglia,
  • Giorgio Vittorio Scagliotti,
  • Paolo Bironzo

DOI
https://doi.org/10.3390/biomedicines11010165
Journal volume & issue
Vol. 11, no. 1
p. 165

Abstract

Read online

Safety data regarding BNT162b2 in cancer patients (CPs) are scarce. Herein we report the side effects (SEs), the adverse events (AEs), and the patient-reported outcomes (PROs) following BNT162b2 administration in CPs treated at the San Luigi Gonzaga University Hospital. All CPs who agreed to participate in our vaccination campaign received BNT162b2 and were included in the descriptive analysis. An anonymous questionnaire investigating the occurrence of SEs/AEs and PROs was administered to the study population 21 days after the first dose. Pearson’s chi-squared test was used to estimate the risk of experiencing SEs/AEs according to selected variables. A total of 997 patients were included in the study: 62.0% had stage IV cancer, and 68.8% were receiving an active treatment, of whom 15.9% were receiving immunotherapy. SEs/AEs were recorded in 37.1% of cases after the first dose and in 48.5% of cases after the second dose. The most common SEs were muscle pain/local rash (27.9% and 28%, after the first and second dose, respectively). Patients older than 70 years showed lower risk of SEs/AEs, while women showed a higher risk. Before receiving the vaccine, 18.2% of patients felt fearful and/or insecure about the vaccination. After the first dose, 57.5% of patients changed their feelings positively. Our data support the short-term safety of BNT162b2 in CPs, regardless of disease stage and concurrent treatments. Overall, the vaccination showed a positive impact on quality of life.

Keywords